Delphi study to identify consensus on patient selection for hydrogel rectal spacer use during radiation therapy for prostate cancer in the UK.
Heather Ann PayneSuneil JainClive PeedellAlbert EdwardsJames Andrew ThomasPrantik DasAmanda Hansson HedblomEmily WoodwardRhodri SaundersAmit BahlPublished in: BMJ open (2022)
There is a strong and general agreement that all patients with prostate cancer undergoing radical radiation therapy have the potential to benefit from hydrogel spacers. Currently, not all patients who could potentially benefit can access hydrogel spacers, and access is unequal. Implementation of the consensus recommendations would likely help prioritise and equalise access to rectal spacers for patients in the UK.
Keyphrases
- prostate cancer
- drug delivery
- radiation therapy
- radical prostatectomy
- end stage renal disease
- hyaluronic acid
- clinical practice
- newly diagnosed
- wound healing
- ejection fraction
- rectal cancer
- chronic kidney disease
- tissue engineering
- primary care
- healthcare
- cross sectional
- peritoneal dialysis
- risk assessment
- patient reported outcomes
- patient reported